BioSpace News Archive

As the world struggles to find the best way to deal with Covid-19, experts agree on one thing: the importance of good testing.

Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product ‘qER’.

Remote Patient Monitoring Solution Provides an Extra Layer of Safety and Offers Peace of Mind For Campus Reopenings

In patients with rheumatoid arthritis, higher disease activity — not post-operative flares — increases the risk of pain and poor function one year after a total hip arthroplasty or total knee arthroplasty, according to a new study by researchers at Hospital for Special Surgery in New York City.

SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treatment of hereditary retinal degenerative diseases such as retinitis pigmentosa, announces today the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies

Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of udenafil to improve the physiology of patients 12 years of age and older with single ventricle heart disease (SVHD) who have undergone the Fontan operation

At the Annual General Meeting of RaySearch Laboratories AB held , the following resolutions were adopted.

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), announce that Pixee Medical, a France-based medical company, in collaboration with Pr. Remy Nizard from Hopital Lariboisière in Paris, France, performed the world’s first Knee+ total knee replacement surgery on June 24th using the Vuzix M400 AR Smart Glasses

Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders.

Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.